CDK4 and breast carcinoma: Consistent benefit with capivasertib–fulvestrant compared with placebo–fulvestrant was observed in clinically relevant subgroups, including in patients with visceral metastases and in those who received prior CDK4/6 inhibitor treatment or prior chemotherapy for advanced breast cancer (Fig. 2).